Document is current
Any future updates will be listed below
-
Authors
Thieme, Elana
Bruss, Nur
Sun, Duanchen
Dominguez, Edward C.
Coleman, Daniel
Liu, Tingting
Roleder, Carly
Martinez, Melissa
Garcia-Mansfield, Krystine
Ball, Brian
Pirrotte, Patrick
Wang, Lili
Xia, Zheng
Danilov, Alexey V. https://orcid.org/0000-0003-4461-0970
-
Funding
Funding for this research was provided by:
Leukemia and Lymphoma Society (R6517-22)
- License Information
-
More Information
Article History
Received: 3 October 2022
Accepted: 14 March 2023
First Online: 30 March 2023
Declarations
:
: Primary samples were obtained under the IRB-approved protocol #18067 at City of Hope. All animal studies were conducted according to institutional guidelines under the IACUC-approved protocol #20006.
: Not applicable.
: A.V.D. has received consulting fees from Abbvie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Meyers Squibb, Genentech, Incyte, Lilly Oncology, Morphposys, Nurix, Oncovalent, Pharmacyclics and TG Therapeutics and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Cyclacel, MEI Pharma, Nurix and Takeda Oncology.
